Austin Neuromuscular Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Austin Neuromuscular Center sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).
Austin Neuromuscular Center: 2 sponsored US clinical trials, 1 recruiting.
Austin Neuromuscular Center sponsors 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Wild-Type Transthyretin Cardiac Amyloidosis, with 1 trials.
Mid-pack sponsor footprint
Austin Neuromuscular Center is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Open and recent trials
2 total, page 1 of 1
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis
NCT06479863
Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran Therapy
NCT05023889
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
What is open in the Austin Neuromuscular Center pipeline
1 recruiting of 2 indexed (50% open).
Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).
Top condition: Wild-Type Transthyretin Cardiac Amyloidosis (1 trial), 6 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Austin Neuromuscular Center: open-pipeline peers nationwide
Peers matched on 2 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
Austin Neuromuscular Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2 trials (± recruiting share)
- 1200 Pharma · 2 trials · 50% recruiting
- 1ST Biotherapeutics · 2 trials · 50% recruiting
- 3 Waves Wellness · 2 trials · 0% recruiting
- 3EO Health · 2 trials · 0% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 3ive Labs · 50% recruiting · 2 trials
- 60 Degrees Pharmaceuticals · 50% recruiting · 4 trials
- 7 Hills Pharma · 50% recruiting · 2 trials
- Abcentra · 50% recruiting · 2 trials
Related
What to do with this Austin Neuromuscular Center page
2 registered trials is a research-attention snapshot, not an endorsement of Austin Neuromuscular Center or any single study.
- 1 of Austin Neuromuscular Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Wild-Type Transthyretin Cardiac Amyloidosis is the condition Austin Neuromuscular Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Wild-Type Transthyretin Cardiac Amyloidosis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Austin Neuromuscular Center pipeline card: 2 registered trials from official public datasets.Report a data error.